GlassScriptPhysician profile
Michael J Larj
NPI 1679507099
$229,005.09
in general payments reported to CMS, 2019-2025
5 companies · $6,140 in 2025
The $6,140 reported for 2025 was more than what 90% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,767 · 2020: $13K · 2021: $78K · 2022: $51K · 2023: $48K · 2024: $23K · 2025: $6,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $74K · Food and Beverage: $2,472 · Travel and Lodging: $1,411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $73,600.00 |
| Food and Beverage | $2,471.66 |
| Travel and Lodging | $1,410.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $172,617.61 | 2019-2025 | Breztri, Airsupra, Symbicort |
| Glaxosmithkline, LLC. | $50,108.11 | 2020-2023 | Arexvy, Nucala |
| Mylan Specialty L.P. | $5,947.65 | 2020-2021 | |
| Genzyme Corporation | $226.10 | 2022-2023 | |
| Mallinckrodt Hospital Products INC. | $105.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Larj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.